Pathological function of prostaglandin E2 receptors in transitional cell carcinoma of the upper urinary tract

Virchows Archiv

Volumn 448, Issue 6, 2006, Pages 822-829

  Miyata, Yasuyoshi ^a   Ohba, Kojiro ^a   Kanda, Shigeru ^a   Nomata, Koichiro ^a   Eguchi, Jiro ^a   Hayashi, Tomayoshi ^b   Kanetake, Hiroshi ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Immunohistochemistry; Prognosis; Protein expression; Transitional cell carcinoma; Upper urinary tract

Indexed keywords

CYCLOOXYGENASE 2; GELATINASE A; HERMES ANTIGEN; ISOPROTEIN; PROSTAGLANDIN E RECEPTOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN E3; UROKINASE;

ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; EXON; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CARCINOMA;

CARCINOMA, TRANSITIONAL CELL; CELL PROLIFERATION; CYCLOOXYGENASE 2; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; IMMUNOENZYME TECHNIQUES; KIDNEY NEOPLASMS; KIDNEY PELVIS; MALE; MICROCIRCULATION; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, PROSTAGLANDIN E; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URETERAL NEOPLASMS;

EID: 33744743313     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-006-0198-1     Document Type: Article

References (38)

1. Arber N, Levin B (2005) Chemoprevention of colorectal cancer: ready for routine use? Recent Results Cancer Res 166:213-230
2. Asano T, Shoda J, Ueda T, Kawamoto T, Todoroki T, Shimonishi M, Tanabe T, Sugimoto Y, Ichikawa A, Mutoh M, Tanaka N, Miwa M (2002) Expression of cyclooxygenase-1 and prostaglandin E-receptors in carcinoma of the gallbladder: crucial role of arachidonate metabolism in tumor growth and progression. Clin Cancer Res 8:1157-1167
3. Braun JR, DuBois RN (2005) COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 23:2840-2855
4. Chang SH, Liu CH, Conway R, Han DK, Nithipatikom K, Trifan OC, Lane TF, Hla T (2004) Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 101:591-596
5. Chen Y, Hugh-Fulfold M (2000) Prostaglandin E2 and the protein kinase A pathway mediate arachidonic acid induction of c-fos in human prostate cancer. Br J Cancer 82:2000-2006
6. Coleman RA, Smith WL, Narumiya S (1994) International union of pharmacology classification of prostanoid receptors: properties, distribution, and structure of the receptors and their subtypes. Pharmacol Rev 46:205-229
7. Dohadwala M, Luo J, Zhu L, Lin Y, Dougherty GJ, Sharma S, Huang M, Pold M, Batra RK, Dubinett SM (2001) Non-small cell cancer cyclooxygenase-dependent invasion is mediated by CD44. J Biol Chem 276:20809-20812
8. Dohadwala M, Bartra RK, Luo J, Lin Y, Krysan K, Põld M, Sharma S, Dubinett SM (2002) Autocrine/paracrine PGE2 production by non-small cell lung cancer cells regulates MMP-2 and CD44 in COC-2 dependent invasion. J Biol Chem 52:50828-50833
9. Dubois RN, Abramson SB, Crofford L, Gupta RA, Simon LS, Van De Putte LB, Lipsky PE (1998) Cyclooxygenase in biology and disease. FASEB J 12:1063-1073
10. Eschwege P, Ferlicot S, Droupy S, Ba N, Conti M, Loric S, Coindard G, Denis I, Ferretti L, Cornelius A, Legrand A, Bedossa P, Benoit G, Jardin A, Scardiono P (2003) A histopathologic investigation of PGE(2) pathways as predictors of proliferation and invasion in urothelial carcinomas of the bladder. Eur Urol 44:435-441
11. min/+ mice. Cancer Res 62:403-408
12. Hong RL, Pu YS, Hsieh TS, Chu JS, Lee WJ (1996) Expressions of E-cadherin and exon v6-containing isoforms of CD44 and their prognostic values in human transitional cell carcinoma. J Urol 153:2025-2028
13. Inoue K, Kamada M, Salton JW, Fukata S, Yoshikawa C, Tamboli P, Dinney CF, Shuin T (2002) The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 8:1863-1870
14. Jabbour HN, Milne SA, Williams AR, Anderson RA, Boddy SC (2001) Expression of COX-2 and PGE synthase and synthesis of PGE(2) in endometrial adenocarcinoma: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. Br J Cancer 85:1023-1031
15. Kawamori T, Uchiya N, Nakatsugi S, Watanabe K, Ohuchida S, Yamamoto H, Maruyama T, Kondo K, Sugimura T, Wakabayashi K (2002) Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP1 antagonists, on breast cancer development. Carcinogenesis 22:2001-2004
16. Kinugasa Y, Hatori M, Ito H, Kurihara Y, Ito D, Nagumo M (2004) Inhibition of cyclooxygenase-2 suppresses invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 and CD44. Clin Exp Metastasis 21:737-745
17. Kömhoff M, Guan Y, Shappell HW, Davis L, Jack G, Shyr Y, Koch MO, Shapper SB, Breyer MD (2000) Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas. Am J Pathol 157:29-35
18. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett SM (2005) Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner. Cancer Res 65:6275-6281
19. Li G, Yang T, Yan J (2002) Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun 299:886-890
20. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, Edwards DA, Flickinger AG, Moore RJ, Seibert K (2000) Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res 60:1306-1311
21. Miyata Y, Koga S, Kanda S, Nishikido M, Hayashi T, Kanetake H (2003) Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res 9:1741-1749
22. Miyata Y, Shigeru K, Nomata K, Hayashida Y, Kanetake H (2004) Expression of metalloproteinase-2, -9, and tissue inhibitor of metalloproteinase-1 and -2 in transitional cells carcinoma of the upper urinary tract: correlation with tumor stage and survival. Urology 63:602-608
23. Miyata Y, Shigeru K, Nomata K, Eguchi J, Kanetake H (2005) Expression of cyclooxygenase-2 and EP4 receptor in transitional cell carcinoma of the upper urinary tract. J Urol 173:56-60
24. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KNM, Masferrer JL, Woerner Snyder PW, Koki AT (1999) Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary bladder. Cancer Res 59:987-990
25. Munkarah A, Ali-Fehmi R (2005) COX-2: a protein with an active role in gynecological cancers. Curr Opin Obstet Gynecol 17:49-53
26. Mutoh M, Watanabe K, Kitamura T, Shoji Y, Takahashi M, Kawamori T, Tani K, Kobayashi M, Maruyama T, Kobayashi K, Ohuchida S, Sugimoto Y, Narumiya S, Sugimura T, Wakabayshi K (2002) Involvement of prostaglandin E receptor subtype EP4 in colon carcinogenesis. Cancer Res 62:28-32
27. Nakanishi K, Kawai T, Torikata C, Aurues T, Ikeda T (1998) Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma. Cancer 82:724-732
28. Nakanishi K, Kawai T, Sato H, Aida S, Kasamatsu H, Aurues T, Ikeda T (2000) Expression of matrix metalloproteinase-2 (MMP-2) and of membrane-type-1matrix metalloproteinase (MT1-MMP) in transitional cell carcinoma of the upper urinary tract. Hum Pathol 31:193-200
29. Rigas B, Goldman IS, Levine L (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122:518-523
30. Sales KJ, Katz AA, Davis M, Hinz S, Soeters RP, Hofmeyr MD, Millar RP, Jabbour HN (2001) Cyclooxygenase-2 expression and prostaglandin E2 synthesis are up-regulated in carcinomas of the cervix: a possible autocrine/paracrine regulation of neoplastic cell function via EP2/EP4 receptors. J Clin Endocrinol Metab 86:2243-2249
31. 2 in human colon cancer cells. Cancer Res 58:326-362
32. Sheng H, Shao J, Washington MK, Dubois RN (2001) Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 276:75-81
33. Toma V, Hauri D, Schmid U, Ackermann D, Maurer R, Alund G, Knönagel H, Rist M, Gasser TC, Sauter G, Roth J (1999) Focal loss of CD44 variant protein expression is related to recurrence in superficial bladder carcinoma. Am J Pathol 155:1427-1432
34. Wendum D, Masliah J, Trugnan G, Flejou JF (2004) Cyclooxygenase-2 and its role in colorectal cancer development. Virchows Arch 445:327-333
35. Yano T, Zissel G, Muller-Qernheim J, Shin SJ, Satoh H, Ichikawa T (2002) Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett 518:154-158
36. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, DeLellis RA, Subbaramaiah K, Dannenberg AJ (2001) Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 7:3971-3976
37. Zha S, Yegnasubramanian V, Nelson WG, Isaacs WB, De Marzo AM (2004) Cyclooxygenases in cancer: progress and perspective. Cancer Lett 215:1-20
38. 2 in human head and neck xenograft tumors. Cancer Res 62:6706-6711